利妥昔单抗生物类似药 (辉瑞制药)(Rituximab-Pvvr) - 药物靶点：CD20_在研适应症：CD20阳性弥漫性大B细胞淋巴瘤，霍奇金淋巴瘤，低级别 B 细胞非霍奇金淋巴瘤_专利_临床

概要

基本信息

药物类型

生物类似药、单克隆抗体

别名

RUXIENCE、Rituximab biosimilar、Rituximab biosimilar (Pfizer)

+ [4]

靶点

CD20

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用

+ [1]

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [5]

在研适应症

CD20阳性弥漫性大B细胞淋巴瘤霍奇金淋巴瘤低级别 B 细胞非霍奇金淋巴瘤+ [14]

非在研适应症

CD20阳性滤泡性淋巴瘤

原研机构

Pfizer Inc.

在研机构

Pfizer Europe MA EEIG

Pfizer Australia Pty Ltd.

Pfizer Japan, Inc.

+ [1]

非在研机构

Pfizer Canada ULC

最高研发阶段批准上市

首次获批日期

美国 (2019-07-23),

CD20阳性B细胞慢性淋巴细胞白血病肉芽肿伴多血管炎显微镜下多血管炎+ [1]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 83181H

当前序列信息引自: *****

Sequence Code 27145L

当前序列信息引自: *****

关联

3

项与利妥昔单抗生物类似药 (辉瑞制药) 相关的临床试验

NCT02213263

/ Completed临床3期

A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

开始日期2014-09-30

申办/合作机构

Pfizer Inc.

NCT01526057

/ Completed临床2期

A RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING THE PHARMACOKINETICS AND PHARMACODYNAMICS, AND ASSESSING THE SAFETY OF PF-05280586 AND RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGROUND OF METHOTREXATE WHO HAVE HAD AN INADEQUATE RESPONSE TO ONE OR MORE TNF ANTAGONIST THERAPIES

In this study, patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab). During the course of the study, the effects of the drugs will be assessed by sampling the levels of drug in the blood, blood cell counts, and by comparing these levels among the different treatments. Safety, tolerability and immunologic response also will be evaluated throughout.

开始日期2012-03-20

申办/合作机构

Pfizer Inc.

NCT00867087

/ Completed临床2期

An Open-label, Single-arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory Cd22-positive Diffuse Large B-cell Lymphoma, Eligible For Autologous Stem Cell Transplantation

The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.

开始日期2009-06-08

申办/合作机构

Pfizer Inc.

[+1]

100 项与利妥昔单抗生物类似药 (辉瑞制药) 相关的临床结果

登录后查看更多信息

100 项与利妥昔单抗生物类似药 (辉瑞制药) 相关的转化医学

登录后查看更多信息

100 项与利妥昔单抗生物类似药 (辉瑞制药) 相关的专利（医药）

登录后查看更多信息

17

项与利妥昔单抗生物类似药 (辉瑞制药) 相关的文献（医药）

2025-01-02·Expert Opinion on Drug Safety

Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database

Article

作者: Xue, Xiangzhong ; Qian, Jingjing

BACKGROUNDBy 31 December 2022, the United States Food and Drug Administration (FDA) has approved 12 biosimilar monoclonal antibody cancer treatments. This study detected disproportionate adverse event (AE) reporting signals and compared safety profile of individual biosimilars to their originator biologics and between each pair of biosimilars.RESEARCH DESIGN AND METHODSThe FDA Adverse Event Reporting System data (6/1/2018-12/31/2022) were used to identify AE reports for rituximab, bevacizumab, trastuzumab, and their marketed biosimilars. Reporting odds ratios and empirical Bayesian geometric mean were computed to detect reporting disproportionality in serious, death, and specific AEs between studied biologics/biosimilars and all other drugs.RESULTSSignificant AE reporting signals were identified: 1) death for biological rituximab, pruritus for biosimilar rituximab-pvvr, and infusion-related reactions for biological rituximab and biosimilar rituximab-pvvr (significantly higher ROR for rituximab-pvvr than biological rituximab, p < .0001); 2) death for biological bevacizumab and biosimilar bevacizumab-bvzr (significantly higher ROR for bevacizumab-bvzr than biological bevacizumab, p < .0001), hypertension, platelet count decreased (PCD), and proteinuria for biological bevacizumab and biosimilar bevacizumab-awwb (significantly higher ROR of PCD for bevacizumab-awwb than originator bevacizumab, p = .001); and 3) rash for biosimilar trastuzumab-anns.CONCLUSIONSFindings call for large, longitudinal studies to examine causality of certain AEs with rituximab-pvvr and bevacizumab biosimilars.

2024-12-18·Cureus

Cutaneous Microthrombosis in a Patient With Factor V Leiden Heterozygosity and Antibodies to Phosphatidylserine/Prothrombin Complex

Article

作者: Nardella, Francis A

This report describes the development of recurrent cutaneous microthrombosis in a patient with the superposition of Factor V Leiden heterozygosity on a noncriteria IgM antibody to phosphatidylserine/prothrombin complex. The patient was treated with prednisone, apixaban, and rituximab and was stable off of prednisone at her last outpatient visit 22 months after the initial event. This report illustrates the challenges of dealing with multifactor thrombophilia especially when one of those factors is a noncriteria antiphospholipid antibody and reaffirms the value of testing for noncriteria antibodies when clinical findings suggest the presence of antiphospholipid antibodies but the criteria antibodies are negative. This report further shows, in this patient, the benefit of the addition of rituximab-pvv to apixaban in normalizing the level of antiphosphatidylserine/prothrombin complex antibodies with the cessation of cutaneous microthrombotic events, normalization of inflammatory markers, and allowing the discontinuation of prednisone. Because of the relatively high frequency of Factor V Leiden heterozygosity in Caucasian populations, this report suggests that dual-factor thromobophilia due to its combination with criteria or noncriteria antiphospholipid antibodies may be more common than is recognized.

2024-07-02·Expert Opinion on Biological Therapy

Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications – an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis

Article

作者: Tennyson, Scott D ; Hufnagel, Heather Rae

PURPOSEEvaluate the type and quantity of quality information (i.e. Chemistry, Manufacturing, and Control) requested by the US FDA and EMA in queries pertaining to biosimilar applications.METHODSNumbers/types of queries received following regulatory submissions (FDA/EMA, n = 7/n = 5) for seven biosimilars (PF-filgrastim [Nivestym], PF-rituximab [Ruxience®], PF-trastuzumab [Trazimera®], PF-bevacizumab [Zirabev®], PF-pegfilgrastim [Nyvepria®], PF-adalimumab [Abrilada™/Amsparity®], PF-infliximab [Ixifi]) from a single product portfolio were analyzed considering published regulatory authority (RA) guidance and in relation to sections/subsections of Module 3: Quality from the Common Technical Document regulatory dossier and topics based on keyword assignment.RESULTSQueries were most frequently assigned (FDA/EMA %, range) to Drug Substance Manufacture (subsection 3.2.S.2; 21-35%/13-50%), Control of Drug Substance (3.2.S.4; 3-11%/5-17%), Drug Product Pharmaceutical Development (3.2.P.2; 1-12%/1-15%) and Manufacture (3.2.P.3; 17-41%/2-13%), and Analytical Similarity (3.2.R; 4-21%/4-20%). The proportion of Drug Substance and Drug Product queries was significantly different between RAs (n1 = 952, n2 = 468, p-value <0.001; two-sample proportion z-test). Topic assignments included: Control (12-27%/12-28%), Manufacturing (56-72%/34-66%), Stability (1-12%/2-24%), Biosimilarity (5-16%/5-25%), and Container Closure (0-3%/0-9%).CONCLUSIONThe focus of both RAs on topics related to manufacturing and controls is valuable in understanding expectations for scientific and technical content related to gaining biosimilar approval.

28

项与利妥昔单抗生物类似药 (辉瑞制药) 相关的新闻（医药）

2024-11-16

·PipelineReview

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease

ALAMEDA, CA, USA and TAIPEI, Taiwan I November 15, 2024 I Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, announced today that it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for the company’s lead candidate ACE 1831 in IgG4-related disease (IgG4-RD), a multi-organ, fibro-inflammatory autoimmune condition. This IND clearance allows Acepodia to investigate the safety and efficacy of Acepodia’s ACE1831 in patients with IgG4-RD, as its first step in autoimmune disease. ACE1831 utilizes bioorthogonal chemistry to link CD20-targeting antibodies to gamma delta T cells, creating an off-the-shelf, non-genetically engineered version of T cell therapy that is more easily scaled and may potentially mitigate side effects associated with autologous CAR-T cell therapies, such as T cell malignancies. ACE1831 is also in a Phase 1 dose escalation study for non-Hodgkin’s lymphoma (NHL). “Based on the observation of clinical benefits of CAR-T in autoimmune diseases, we hope to prove that ACE1831 can deliver ‘deeper’ B cell depletion than antibody drugs, critical for longer remission in autoimmune diseases,” said Sonny Hsiao, PhD, Chief Executive Officer, President and Co-Founder of Acepodia. “We’ve engaged accomplished IgG4-RD research physicians worldwide, excited by our innovative approach. This clearance enables us to launch the study, offering participants a promising new treatment,” commented Jerry Liu, MD, Head of Clinical Development of Acepodia. The Phase 1b/2a study of ACE1831 will be executed in collaboration with Pfizer Ignite, a service that offers biotech companies access to Pfizer’s significant resources, scale, and expertise to accelerate the progression of potential breakthrough medicines for patients. The study will be led by Dr. John Stone, MD, MPH, of Massachusetts General Hospital, Executive Chairman of The IgG4ward! Foundation and an eminent IgG4-RD researcher whose work identified the potential of targeted B-cell depletion with rituximab. Dr. Stone said, “A crucial finding for people living with IgG4-RD now has been the efficacy in disease control exerted by B cell depletion. I’m enthusiastic now not only about the possibility of deeper B cell depletion with Acepodia’s approach, but also about its ease of use and potential for fewer adverse effects than other cell-based approaches.” About Acepodia Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells, to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens as well as pathogenic B cells causing autoimmune disease. Acepodia is composed of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. For more information, visit www.acepodia.com and follow Acepodia on Twitter and LinkedIn . SOURCE: Acepodia

细胞疗法临床申请免疫疗法临床1期

2024-11-15

·PRNewswire

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) The planned clinical study will be executed as part of strategic clinical collaboration with Pfizer Ignite ALAMEDA, Calif. and TAIPEI, Nov. 15, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, announced today that it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for the company's lead candidate ACE 1831 in IgG4-related disease (IgG4-RD), a multi-organ, fibro-inflammatory autoimmune condition. This IND clearance allows Acepodia to investigate the safety and efficacy of Acepodia's ACE1831 in patients with IgG4-RD, as its first step in autoimmune disease. ACE1831 utilizes bioorthogonal chemistry to link CD20-targeting antibodies to gamma delta T cells, creating an off-the-shelf, non-genetically engineered version of T cell therapy that is more easily scaled and may potentially mitigate side effects associated with autologous CAR-T cell therapies, such as T cell malignancies. ACE1831 is also in a Phase 1 dose escalation study for non-Hodgkin's lymphoma (NHL). "Based on the observation of clinical benefits of CAR-T in autoimmune diseases, we hope to prove that ACE1831 can deliver 'deeper' B cell depletion than antibody drugs, critical for longer remission in autoimmune diseases," said Sonny Hsiao, PhD, Chief Executive Officer, President and Co-Founder of Acepodia. "We've engaged accomplished IgG4-RD research physicians worldwide, excited by our innovative approach. This clearance enables us to launch the study, offering participants a promising new treatment," commented Jerry Liu, MD, Head of Clinical Development of Acepodia. The Phase 1b/2a study of ACE1831 will be executed in collaboration with Pfizer Ignite, a service that offers biotech companies access to Pfizer's significant resources, scale, and expertise to accelerate the progression of potential breakthrough medicines for patients. The study will be led by Dr. John Stone, MD, MPH, of Massachusetts General Hospital, Executive Chairman of The IgG4ward! Foundation and an eminent IgG4-RD researcher whose work identified the potential of targeted B-cell depletion with rituximab. Dr. Stone said, "A crucial finding for people living with IgG4-RD now has been the efficacy in disease control exerted by B cell depletion. I'm enthusiastic now not only about the possibility of deeper B cell depletion with Acepodia's approach, but also about its ease of use and potential for fewer adverse effects than other cell-based approaches." About Acepodia Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells, to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens as well as pathogenic B cells causing autoimmune disease. Acepodia is composed of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. For more information, visit and follow Acepodia on Twitter and LinkedIn. SOURCE Acepodia Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

细胞疗法临床申请免疫疗法临床1期

2024-08-21

·空之客

【医苑观畴】2024年二季度海外药企进展更新：辉瑞PFE

1 整体表现曾经的宇宙第一大厂辉瑞，在新冠口服药和疫苗的潮水迅速退去的过程中，仿佛又回到了业绩增长点全线哑火的尴尬境地，于是市值从22年最风光时短暂达到过的$300b、近期又回到了$150b左右，在大药企的市值排名一下落到第9名（顺便吐个槽，自从疫情结束后，PFE看点急剧衰竭的程度从季报篇幅的缩水就可见一斑，这家顶级MNC的季报如果不算封面封底脚注居然只有10页纸……）扣除新冠产品以外的收入同比增长14%，但其实其中也有一大半的增量又是来源于合并SGEN那些ADC产品，所以实际上可比的内生增长依然非常微不足道，而且净利润也在下降。 2 已上市产品肿瘤板块的业绩只能说是小打小闹，最粗的大腿Palbociclib早已日薄西山，Enzalutamide看起来在联用PARP抑制剂获批之后确实对销售额颇有贡献、LTM累计已达到$1.5b，BRAF+MEK组合这个季度也有所起色、单季$150m，不过$43b重金买来的SGEN单季度只贡献了区区$827m、爬坡也算不上明显、不知道距离2030年贡献超过$10b这个目标还有多远。免疫炎症板块更是惨不忍睹，老迈不堪的Tofacitinib和Etanercept正在一路下滑，而新一代JAK抑制剂Abrocitinib上市两年多LTM累计才$163m，与单季度都已经$1.4b的Upadacitinib一比简直高下立判。传染病板块里，除去新冠两兄弟的一地鸡毛，也就靠LTM累计$6.5b的肺炎疫苗Prevnar独撑危局了，新上市的RSV疫苗Abrysvo首个年度打破$1b大关也算给未来留下看点。其他产品倒是看点颇多：Apixaban还算是老骥伏枥，加上BMS部分LTM累计已接近$20b大关；TTR稳定剂Tafamidis划出一条完美的成长曲线，LTM累计已高达$4.3b，尽管面对后续ALNY和BBIO的潜在冲击，至少已经证明ATTR-CM/PN的确是有巨大潜力的适应症（参见【药海听涛】太阳神终于降临：Alnylam公布HELIOS-B三期结果）；偏头痛药物Rimegepant也改出了此前几个季度走平的状态，LTM累计突破$1.0b，至少作为同适应症药物已经超越了LLY的Galcanezumab、ABBV的Atogepant和Ubrogepant、NVS的Erenumab，成为偏头痛和CGRP中市场份额的领跑者。 3 在研管线这个季度PFE最吸睛的消息就是小分子GLP-1的“借尸还魂”，在此前终止了Danuglipron每日两次剂型的开发后，每日一次控释剂型的优化完成并准备启动桥接试验。基因治疗好像久远得像上古时代的产物，PFE曾经在这里砸下的重金也总算听到点儿回响，治疗A型血友病的AAV项目SB-525读出了三期临床的topline数据，从输注后第12周到至少15个月的随访期间，单次3e13 vg/kg SB-525与八因子替代预防疗法相比，平均总年化出血率（ABR）为1.24 vs 4.73（p=0.0040）；然而另一个治疗DMD的AAV项目却遭遇三期临床失败。除此以外，值得关注的进展还包括：Adcetris公布了联用Lenalidomide和Rituximab治疗DLBCL的三期临床数据并提交sBLA，长效生长激素Somatrogon向欧洲药监部门提交上市申请，RSV疫苗Abrysvo公布了免疫低下成年人群的三期临床数据、并获批Act-O-Vial剂型，BCMA/CD3双抗Elranatamab公布二期临床中1L MM亚组的OS数据，。说得不客气点，PFE就像一具被新冠业务吸干了精气的僵尸，庞大的身躯虽然仍有动作，却表现出令人费解的茫然混沌，早已失去了曾经作为宇宙第一大药企的方向感和驱动力。从他其实早早发了季报，我直到现在才愿意细看一眼（然而并没看到什么值得期待的内容），就知道期望值有多低……

疫苗临床3期基因疗法财报引进/卖出

100 项与利妥昔单抗生物类似药 (辉瑞制药) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	利妥昔单抗生物类似药 (辉瑞制药)	L01XC02	DB00073

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
CD20阳性的B细胞非霍奇金淋巴瘤	列支敦士登	Pfizer Europe MA EEIG	2020-04-01
CD20阳性的B细胞非霍奇金淋巴瘤	欧盟	Pfizer Europe MA EEIG	2020-04-01
CD20阳性的B细胞非霍奇金淋巴瘤	冰岛	Pfizer Europe MA EEIG	2020-04-01
CD20阳性的B细胞非霍奇金淋巴瘤	挪威	Pfizer Europe MA EEIG	2020-04-01
难治性慢性淋巴细胞白血病	欧盟	Pfizer Europe MA EEIG	2020-04-01
难治性慢性淋巴细胞白血病	列支敦士登	Pfizer Europe MA EEIG	2020-04-01
难治性慢性淋巴细胞白血病	冰岛	Pfizer Europe MA EEIG	2020-04-01
难治性慢性淋巴细胞白血病	挪威	Pfizer Europe MA EEIG	2020-04-01
滤泡性淋巴瘤	列支敦士登	Pfizer Europe MA EEIG	2020-04-01
滤泡性淋巴瘤	挪威	Pfizer Europe MA EEIG	2020-04-01
滤泡性淋巴瘤	欧盟	Pfizer Europe MA EEIG	2020-04-01
滤泡性淋巴瘤	冰岛	Pfizer Europe MA EEIG	2020-04-01
类风湿关节炎	列支敦士登	Pfizer Europe MA EEIG	2020-04-01
类风湿关节炎	冰岛	Pfizer Europe MA EEIG	2020-04-01
CD20阳性B细胞淋巴瘤	日本	Pfizer Japan, Inc.	2019-09-20
CD20阳性非霍奇金淋巴瘤	日本	Pfizer Japan, Inc.	2019-09-20
CD20阳性B细胞慢性淋巴细胞白血病	美国	Pfizer Inc.	2019-07-23
肉芽肿伴多血管炎	美国	Pfizer Inc.	2019-07-23
显微镜下多血管炎	美国	Pfizer Inc.	2019-07-23
非霍奇金淋巴瘤	美国	Pfizer Inc.	2019-07-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
CD20阳性滤泡性淋巴瘤	临床3期	葡萄牙	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	克罗地亚	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	韩国	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	墨西哥	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	菲律宾	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	希腊	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	西班牙	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	白俄罗斯	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	英国	Pfizer Inc.	2014-09-30
非霍奇金淋巴瘤	临床前	加拿大	Pfizer Canada ULC	2019-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02213263 (Not provided \| REFLECTIONS, Pubmed \| BioDrugs)	临床3期	CD20阳性滤泡性淋巴瘤	394	PF-05280586	(簾構構鬱選襯齋齋鏇獵) = 齋鑰淵廠鬱廠廠鹹遞製網鏇選醖選積淵齋壓願 (窪獵構齋膚齋餘艱艱醖 ) 更多	-	2020-04-01
NCT02213263 (Not provided \| REFLECTIONS, Pubmed \| BioDrugs)	临床3期	CD20阳性滤泡性淋巴瘤	394	Rituximab Reference Product (MabThera®)	(簾構構鬱選襯齋齋鏇獵) = 夢願簾構艱選積獵鹽夢網鏇選醖選積淵齋壓願 (窪獵構齋膚齋餘艱艱醖 ) 更多	-	2020-04-01
NCT01526057 (REFLECTIONS, CTgov)	临床2期	类风湿关节炎	220	Rituximab (Rituximab-Pfizer)	淵窪築淵獵範艱獵膚簾(網範簾壓獵鏇網艱淵構) = 積餘憲範衊鹹鹽夢觸網簾範齋醖鑰壓夢繭憲選 (餘蓋範膚壓網願選衊膚, 繭餘觸膚淵壓衊醖蓋廠 ~ 蓋壓製鏇衊築窪齋鏇襯) 更多	-	2019-11-19
NCT01526057 (REFLECTIONS, CTgov)	临床2期	类风湿关节炎	220	Rituximab (Rituximab-EU)	淵窪築淵獵範艱獵膚簾(網範簾壓獵鏇網艱淵構) = 顧膚積願鏇繭齋簾淵獵簾範齋醖鑰壓夢繭憲選 (餘蓋範膚壓網願選衊膚, 選憲鬱糧蓋夢網鑰顧醖 ~ 簾繭遞願淵獵鏇積蓋繭) 更多	-	2019-11-19
NCT02213263 (REFLECTIONS, ASH 12018 \| ASH 22018) 人工标引	临床3期	CD20阳性滤泡性淋巴瘤一线 CD20 Positive	394	PF-05280586	(選鬱簾餘艱網窪膚範壓) = 艱窪選憲構選廠鹹醖繭選鹽淵鬱憲夢糧顧膚網 (構廠齋壓窪淵網蓋選製 ) 更多	相似	2018-11-29
NCT02213263 (REFLECTIONS, ASH 12018 \| ASH 22018) 人工标引	临床3期	CD20阳性滤泡性淋巴瘤一线 CD20 Positive	394	Rituximab-EU	(選鬱簾餘艱網窪膚範壓) = 鹽齋襯窪艱糧餘顧選構選鹽淵鬱憲夢糧顧膚網 (構廠齋壓窪淵網蓋選製 ) 更多	相似	2018-11-29
NCT02213263 (Not provided \| REFLECTIONS, CTgov)	临床3期	CD20阳性滤泡性淋巴瘤	394	PF-05280586	糧製憲鬱遞鹽鹽築窪積(糧遞選艱願襯衊窪遞獵) = 簾鏇艱蓋廠觸襯顧醖夢醖範糧齋糧膚壓鹹築膚 (淵憲範範壓憲夢齋憲衊, 夢壓顧選鏇襯積膚艱壓 ~ 製鏇構鏇壓廠衊鹹鹽膚) 更多	-	2018-10-30
NCT00867087 (CTgov)	临床2期	复发性弥漫性大B细胞淋巴瘤	64	rituximab+inotuzumab ozogamicin (CMC-544)	鹽鏇廠艱衊餘膚鬱鬱艱(蓋蓋遞夢鏇繭艱艱膚鑰) = 積鑰鹽夢餘獵憲鏇齋構壓網鹽範網襯齋網觸餘 (顧構夢糧鹹壓範憲齋鬱, 顧鑰夢構糧淵憲餘廠窪 ~ 獵鏇製窪衊鑰鹹鑰艱簾) 更多	-	2017-08-22
EHA2015	N/A	慢性淋巴细胞白血病	16	Pentostatin Cyclophosphamide Rituximab (PCR) regimen	(壓願衊襯繭鏇築簾艱艱) = 觸築鹹觸築窪餘鬱膚構膚鏇艱繭築鏇鏇願鹽獵 (衊築夢衊鬱獵蓋齋築鑰 ) 更多	-	2015-05-21